Literature DB >> 9867748

Prevalence of hereditary hemochromatosis in 16031 primary care patients.

P D Phatak1, R L Sham, R F Raubertas, K Dunnigan, M T O'Leary, C Braggins, J D Cappuccio.   

Abstract

BACKGROUND: Despite evidence from screening studies in northern European populations, the prevalence of hemochromatosis in primary care populations in the United States remains speculative.
OBJECTIVE: To establish the feasibility of screening for hemochromatosis and to estimate the prevalence of hemochromatosis in a large primary care population.
DESIGN: Cross-sectional prevalence study.
SETTING: 22 primary care practices in the Rochester, New York, area. PATIENTS: 16031 ambulatory patients without a previous diagnosis of hemochromatosis. INTERVENTION: Serum transferrin saturation screening tests were offered to all adult patients in participating primary care practices. MEASUREMENTS: Patients with a serum transferrin saturation of 45% or more on initial testing had a serum transferrin saturation test done under fasting conditions and had serum ferritin levels measured. Those who had a fasting serum transferrin saturation of 55% or more and a serum ferritin level of 200 microg/L or more with no other apparent cause were presumed to have hemochromatosis and were offered liver biopsy to confirm the diagnosis.
RESULTS: 25 patients had biopsy-proven hemochromatosis; 22 patients met the clinical criteria for hemochromatosis but declined liver biopsy and were classified as having clinically proven hemochromatosis; and 23 patients had a serum transferrin saturation of 55% or more with no identifiable cause, indicating probable hemochromatosis. The prevalence of clinically proven and biopsy-proven hemochromatosis combined was 4.5 per 1000 (95% CI, 3.3 to 5.8 per 1000) in the total sample and 5.4 per 1000 (CI, 4.0 to 7.1 per 1000) in white persons. The prevalence was higher in men than in women (ratio, 1.8:1).
CONCLUSIONS: Hemochromatosis is relatively common among white persons. Routine screening of white persons for hemochromatosis should be considered by primary care physicians.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9867748     DOI: 10.7326/0003-4819-129-11_part_2-199812011-00006

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  19 in total

1.  Population screening for haemochromatosis.

Authors:  P C Adams
Journal:  Gut       Date:  2000-03       Impact factor: 23.059

2.  Hereditary haemochromatosis: never seen a case?

Authors:  J Emery; P Rose
Journal:  Br J Gen Pract       Date:  2001-05       Impact factor: 5.386

3.  The case for strengthening education and training for general practice.

Authors:  T van Zwanenberg; M Pringle; S Smail; M Baker; S Field
Journal:  Br J Gen Pract       Date:  2001-05       Impact factor: 5.386

4.  Changes in exercise capacity in subjects with cardiac asymptomatic hereditary hemochromatosis during a follow-up after 5 yrs.

Authors:  Yukitaka Shizukuda; Kevin P Smith; Dorothy J Tripodi; Ross Arena; Yu-Ying Yau; Charles D Bolan; Myron A Waclawiw; Susan F Leitman; Douglas R Rosing
Journal:  Am J Phys Med Rehabil       Date:  2012-05       Impact factor: 2.159

5.  Seroprevalence of antibodies to microorganisms known to cause arterial and myocardial damage in patients with or without coronary stenosis.

Authors:  C Stöllberger; G Mölzer; J Finsterer
Journal:  Clin Diagn Lab Immunol       Date:  2001-09

Review 6.  Population screening for hemochromatosis: has the time finally come?

Authors:  J C Barton; R T Acton
Journal:  Curr Gastroenterol Rep       Date:  2000-02

7.  Hereditary hemochromatosis: insights from the Hemochromatosis and Iron Overload Screening (HEIRS) Study.

Authors:  Gordon D McLaren; Victor R Gordeuk
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2009

8.  Relationship between gene expression of duodenal iron transporters and iron stores in hemochromatosis subjects.

Authors:  James E Nelson; Virginia R Mugford; Ellen Kilcourse; Richard S Wang; Kris V Kowdley
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-11-05       Impact factor: 4.052

9.  Clinical manifestations of hemochromatosis in HFE C282Y homozygotes identified by screening.

Authors:  Gordon D McLaren; Christine E McLaren; Paul C Adams; James C Barton; David M Reboussin; Victor R Gordeuk; Ronald T Acton; Emily L Harris; Mark R Speechley; Phyliss Sholinsky; Fitzroy W Dawkins; Beverly M Snively; Thomas M Vogt; John H Eckfeldt
Journal:  Can J Gastroenterol       Date:  2008-11       Impact factor: 3.522

10.  The role of MR imaging in detection of hepatic iron overload in patients with cirrhosis of different origins.

Authors:  Edyta Szurowska; Katarzyna Sikorska; E Izycka-Swieszewska; Tomasz Nowicki; Tomasz Romanowski; Krzysztof P Bielawski; Michał Studniarek
Journal:  BMC Gastroenterol       Date:  2010-01-27       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.